Drug intelligence / Profile preview

BI 3009947

Development stage: Unknown
Lead developer: Boehringer
Modality: Small Molecules
Administration: Oral

Overview

BI 3009947 is an investigational, orally administered small‑molecule drug being developed by Boehringer Ingelheim for an undisclosed indication. It is currently in early clinical evaluation in healthy male volunteers in a single-rising-dose and relative bioavailability study assessing safety, tolerability, pharmacokinetics, and the impact of different formulations and food on systemic exposure.[1][2][3][4][7][12] The molecular target, mechanism of action, and therapeutic area have not yet been publicly disclosed, and the compound remains in Phase 1 development with no approved indications.[3][4][9][12]

Beyond the preview

Go deeper on BI 3009947.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BI 3009947.

Explore the full profile